SEC chair backs “minimum effective dose” disclosure and targeted tokenization pilots

The U.S. Securities and Exchange Commission (SEC) is signaling support for streamlined “minimum effective dose” disclosure rules and tightly scoped equity‑tokenization pilots via an innovation exemption, according to new remarks from Chair Paul S. Atkins.

The U.S. Securities and Exchange Commission (SEC) is signaling support for streamlined disclosure rules and controlled experiments with equity tokenization, according to a new speech by Chair Paul S. Atkins at the agency’s Investor Advisory Committee meeting.​

Atkins focused first on cutting what he called unnecessary disclosure burdens, arguing for a “minimum effective dose” approach to regulation that keeps rules tightly centered on material information and adapts requirements to company size. He also proposed extending the JOBS Act “IPO on‑ramp” regime, giving small and mid-size firms a longer glide path with scaled reporting so that more issuers are willing to go public.​

On tokenization, Atkins took a more openly experimental stance, arguing that turning equity securities into digital tokens can improve settlement efficiency, reduce settlement risk, and strip out unnecessary intermediaries. He revealed that the SEC is considering an “innovative exemption mechanism” to allow limited trading of specific tokenized securities, using tightly scoped pilots to build experience for a long-term regulatory framework.​

That approach would effectively let tokenized equity projects move forward under controlled conditions, rather than waiting for a full top‑down rule overhaul. For crypto markets, the message is clear: the SEC is not ready to rewrite securities law for tokenization, but it is prepared to grant targeted exemptions that could bring regulated, on‑chain equity settlement closer to reality.